Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 59%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Natera is positioned for strong growth due to their key product offerings and expanding global reach, as evidenced by their PMDA approval and contracts with biopharmaceutical companies. The launch of their new rare disease testing product and strong revenue growth further solidify their positive outlook, leading analysts to rate the company as Outperform. Additionally, the company's success has been attributed to their strong leadership, innovative technology, and ability to identify important factors for growth.

Bears say

Natera is a leading diagnostics company in the rapidly growing molecular residual disease (MRD) space, with a market share of over 90%. However, the company's current valuation is significantly overhyped and overvalued, making it vulnerable to potential setbacks in its growth prospects. Moreover, the MRD market presents significant competition risks, as more and more major diagnostics companies enter the space, potentially challenging Natera's leadership position. Additionally, while the company has a strong pipeline of potential catalysts in the near future, including regulatory approvals and potential expansions into new markets, there is no guarantee that these will translate into significant revenue growth in the long term. Ultimately, the lofty premium at which Natera's stock is currently trading and the potential challenges it faces in sustaining its growth trajectory make it a risky bet for investors.

Natera (NTRA) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 59% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 17 analysts, Natera (NTRA) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $273.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $273.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.